Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
ProQR ( (PRQR) ) has issued an announcement.
On May 4, 2026, ProQR Therapeutics announced that its Annual General Meeting of Shareholders will be held on June 2, 2026, at the offices of Allen Overy Shearman Sterling LLP in Amsterdam, the Netherlands. The company has made the AGM notice, agenda, explanatory notes, proposed amendments to its articles of association, and proxy materials available through its website and regulatory filings, enabling shareholders to prepare for and participate in the meeting.
The most recent analyst rating on (PRQR) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on ProQR stock, see the PRQR Stock Forecast page.
Spark’s Take on PRQR Stock
According to Spark, TipRanks’ AI Analyst, PRQR is a Neutral.
The score is held back primarily by weak financial performance (persistent losses and renewed heavy cash burn) and a negative P/E that underscores lack of profitability. Technicals provide some support due to improving price momentum above key moving averages.
To see Spark’s full report on PRQR stock, click here.
More about ProQR
ProQR Therapeutics N.V. is a clinical-stage biotechnology company focused on developing transformative RNA therapies using its proprietary Axiomer RNA base-editing platform. The company aims to correct disease-causing mutations or modulate protein expression via editing oligonucleotides that recruit endogenous ADAR enzymes, targeting both rare and prevalent diseases with significant unmet medical need.
Average Trading Volume: 526,854
Technical Sentiment Signal: Sell
Current Market Cap: $163.3M
For an in-depth examination of PRQR stock, go to TipRanks’ Overview page.